The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

It is now becoming clear that less differentiated naive and memory T cells are superior to
effector T cells in the transfer of immunity for adoptive cell therapy. This review will outline …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …

Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited
functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) …

Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however,
only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases …

In view of recent reports documenting pervasive translation outside of canonical protein-
coding sequences, we wished to determine the proportion of major histocompatibility …

The biological determinants of sensitivity and resistance to immune checkpoint blockers are
not completely understood. To elucidate the role of intratumoral T-cells and their association …

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …

Immune checkpoint inhibition has been shown to successfully reactivate endogenous T cell
responses directed against tumor-associated antigens, resulting in significantly prolonged …